Brimonidine tartrate NDC 82182-773

NDC codes

FDA NDC Directory

Product NDC (as listed)82182-773Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82182-0773Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
82182-773-05	82182077305	1 BOTTLE, DROPPER in 1 CARTON (82182-773-05) / 5 mL in 1 BOTTLE, DROPPERMarketed from Feb 28, 2022
82182-773-10	82182077310	1 BOTTLE, DROPPER in 1 CARTON (82182-773-10) / 10 mL in 1 BOTTLE, DROPPERMarketed from Feb 28, 2022
82182-773-15	82182077315	1 BOTTLE, DROPPER in 1 CARTON (82182-773-15) / 15 mL in 1 BOTTLE, DROPPERMarketed from Feb 28, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Brimonidine tartrate
Generic name (nonproprietary): brimonidine tartrate
Active ingredients: Brimonidine tartrate — 1.5 mg/mL
Dosage form: Solution/ drops
Route: Ophthalmic
Labeler: Pacific Pharma, Inc.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 021262
Marketing start: Feb 28, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Agonists (Mechanism)
Identifiers: Product ID 82182-773_63e74b48-0ee2-40e8-a81f-008103768e17SPL ID 63e74b48-0ee2-40e8-a81f-008103768e17SPL set ID 5c4aea88-95ca-4da8-a3da-02f10c8b6623RxCUI 861204, 861208UNII 4S9CL2DY2H
Pharmacologic class: alpha-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482182077305 followed by a unit qualifier and the quantity

Package 82182-0773-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 18, 2025.

Indications (excerpt from the label)

Brimonidine tartrate ophthalmic solution 0.1% or 0.15% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brimonidine tartrate ophthalmic solution 0.1% or 0.15% is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021262

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021262
Product	Strength	Form · route	Labeler	Product NDC
Alphagan Pbrimonidine tartrate	Brimonidine tartrate 1.5 mg/mL	Solution/ dropsOphthalmic	Allergan, Inc.	0023-9177